米托蒽醌+甲泼尼龙治疗复发缓解型MS的价值  

Clinical Value of Mitoxantrone Combined with Methylprednisolone in the Treatment of Relapsing-remitting Multiple Sclerosis

作　　者：赵东慧[1] ZHAO Dong-hui(The Second Department of Neurology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang Province,China)

机构地区：[1]黑龙江省佳木斯市中心医院,黑龙江佳木斯154002

出　　处：《罕少疾病杂志》2023年第4期93-94,共2页Journal of Rare and Uncommon Diseases

摘　　要：目的探究米托蒽醌+甲泼尼龙治疗复发缓解型多发性硬化的临床价值。方法选取40例于2020年3月至2021年9月在本院治疗的复发缓解型多发性硬化病人为研究对象,通过随机数字表法分成对照组(n=20)和观察组(n=20),分别予以甲泼尼龙治疗与米托蒽醌联合甲泼尼龙治疗,比较两组临床疗效、扩展残疾状态量表(EDSS)评分、MRI增强病灶数目、血清MMP9含量及不良反应总发生率。结果:观察组治疗总有效率高于对照组;治疗6个月后,观察组EDSS评分、血清基质金属蛋白酶9(MMP9)含量低于对照组,MRI增强病灶数目少于对照组,差异有统计学意义(P<0.05);观察组不良反应总发生率低于对照组,差异无统计学意义(P>0.05)。结论对复发缓解型多发性硬化患者实施米托蒽醌联合甲泼尼龙治疗,在神经功能改善、减少病灶数目,调节血清MMP9含量等方面均具有突出优势,且临床用药安全可靠。Objective To explore the clinical value of mitoxantrone+methylprednisolone in the treatment of relapsing-remitting multiple sclerosis.Methods 40 patients with relapsing-remitting multiple sclerosis who were treated in our hospital from March 2020 to September 2021 were selected as the research objects,and divided into the control group(n=20)and the observation group(n=20)by random number table method 20,methylprednisolone treatment and mitoxantrone combined methylprednisolone treatment were given respectively,and the clinical efficacy,Extended Disability Status Scale(EDSS)score,number of MRI-enhanced lesions,serum MMP9 content and total incidence of adverse reactions were compared between the two groups.Results The total effective rate of observation group was higher than control group.After 6 months of treatment,EDSS score and serum matrix metalloproteinase 9(MMP9)content in the observation group were lower than those in the control group,and the number of MRI enhanced lesions was less than that in the control group,the difference was statistically significant(P<0.05).The total incidence of adverse reactions in observation group was lower than that in control group,and the difference was not statistically significant(P>0.05).Conclusion Mitoxantrone combined with methylprednisolone has a significant effect in the treatment of relapsing-remitting multiple sclerosis,and has outstanding advantages in improving neurological function,reducing the number of lesions,and regulating serum MMP9 levels,and clinical medication is safe and reliable.

关 键 词：米托蒽醌 甲泼尼龙 复发缓解型多发性硬化 神经功能 MRI增强病灶数目、基质金属蛋白酶9 

分 类 号：R445.2[医药卫生—影像医学与核医学]